Detail akcie Heron Therapeutics online

Business Summary: Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Heron Therapeutics Inc revenues increased 7% to $154.9M. Net loss increased 49% to $20.2M. Revenues reflect SUSTOL segment increase from $14.1M to $38.1M, APONVIE segment increase of 88% to $8.5M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.09 to -$0.12.